Finding and drugging the vulnerabilities of RAS-dependent cancers.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 19490885.
- Also identified by DOI 10.1016/j.cell.2009.05.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Kinase inhibitors have ushered in the era of targeted therapy, but their utility to date is primarily limited to cancers bearing oncogenic kinase mutations. Two papers in this issue (Luo et al., 2009; Scholl et al., 2009) could change this landscape by uncovering kinase-specific vulnerabilities in tumors with RAS mutations.
Medical subject headings
- Neoplasms
- Protein Kinase Inhibitors
- ras Proteins